How Individualized Gene and RNA Therapies Could Change Treatment for Ultra-Rare Diseases

Photo by Oldiefan on Pixabay.

How Individualized Gene and RNA Therapies Could Change Treatment for Ultra-Rare Diseases

For people with an ultra-rare genetic disorder, the obstacle is often not a lack of biological understanding. Researchers may know the affected gene, the damaging variant, and even a plausible way to correct its consequences. The harder problem is turning that knowledge into a treatment when only a handful of people, or perhaps one person, could receive it.

Conventional drug development depends on standardized products, sizable clinical trials, and markets large enough to recover years of research and manufacturing costs. That model becomes difficult when a disease is exceptionally uncommon or when each affected person carries a different pathogenic variant. Individualized gene and RNA therapies attempt to bridge this gap by designing a medicine around a patient's specific molecular defect.

The idea does not imply that every component must be created from scratch. In many cases, developers hope to reuse delivery systems, manufacturing procedures, toxicology data, and analytical methods while changing only the sequence that gives the therapy its biological specificity. If regulators and researchers can determine which elements are transferable, individualized treatment could become a repeatable process rather than a succession of isolated experiments.

What individualized treatment means

Precision medicine already divides diseases into molecular subtypes and directs patients toward therapies likely to work for those subtypes. Individualized therapy goes further. A treatment may be designed for one pathogenic variant, one family, or one person.

There is no single technical definition. An antisense oligonucleotide might be created to correct a unique RNA splicing error. A gene editing system could be programmed to repair a particular DNA sequence. A gene replacement vector might use a standard delivery shell but carry a gene cassette selected for a narrowly defined disorder. These approaches differ substantially in durability, risk, manufacturing, and regulatory complexity.

The distinction matters because a medicine for one person cannot be evaluated in the same way as a widely prescribed tablet. Yet individualized does not mean exempt from scientific standards. Developers still need reliable evidence that the molecular diagnosis is correct, that the intervention reaches the relevant tissue, and that its anticipated benefits justify its risks.

RNA therapies offer a comparatively adaptable route

RNA is an attractive target because it sits between DNA and protein. Manipulating RNA can change how much protein a cell produces, how an RNA transcript is spliced, or whether a harmful transcript is destroyed. In many cases, this can be done without permanently changing the genome.

Antisense oligonucleotides, usually called ASOs, are short synthetic strands designed to bind a selected RNA sequence. Depending on their chemistry and target, they can alter splicing, reduce RNA abundance, or block interactions involved in gene expression. Once a development team has experience with a particular chemical backbone and route of administration, the nucleotide sequence can sometimes be changed while much of the broader production process remains similar.

The best known individualized example is milasen, an ASO developed for a child with a rare form of Batten disease caused by a unique insertion that disrupted RNA splicing. The treatment was designed to restore more normal splicing. The published case report in The New England Journal of Medicine described the scientific, manufacturing, regulatory, and clinical work required to move from diagnosis to treatment.

Milasen established that a patient-specific oligonucleotide could be produced and administered under regulatory oversight. It did not establish that such treatment will reliably reverse advanced neurodegeneration. A single case cannot separate treatment effects from natural variation, supportive care, or measurement uncertainty. Its importance lies primarily in demonstrating feasibility and revealing the infrastructure needed for future cases.

Other RNA technologies may eventually broaden the range of addressable variants. Small interfering RNA can reduce production of harmful proteins. RNA editing systems seek to change selected RNA letters without modifying DNA. Messenger RNA can temporarily instruct cells to produce a missing protein. Some of these methods are already used in broader therapeutic settings, while highly individualized applications remain experimental.

RNA treatments also have limitations. Their effects are generally temporary, so repeated dosing may be necessary. Distribution to the brain, muscle, eye, lung, and other tissues varies with molecular chemistry and delivery method. An oligonucleotide designed for the correct sequence may still cause toxicity through unintended binding, immune activation, or chemical properties shared across its drug class.

Gene replacement and editing address different problems

Gene replacement aims to provide cells with a functional copy of a gene. Adeno-associated viral vectors are commonly studied for this purpose because they can deliver genetic material to several tissues and generally do not reproduce on their own. They are most suitable when the required genetic cargo fits within the vector's capacity and when adding a functional gene is biologically appropriate.

For ultra-rare diseases, a reusable vector platform could potentially carry different therapeutic genes while relying on established production and testing procedures. This is one objective of the Bespoke Gene Therapy Consortium, a public and private collaboration working to develop shared approaches for adeno-associated virus gene therapies for rare diseases.

Gene replacement is not simply a matter of inserting a new sequence into a standard container. Changing the gene cassette can affect expression, stability, potency, and toxicity. The target tissue may require a different viral capsid or route of administration. Preexisting immunity can prevent effective delivery, and treatment may provoke immune responses against the vector or the newly produced protein. Redosing can also be difficult because the immune system may recognize the vector after the first exposure.

Genome editing seeks to alter DNA more directly. CRISPR-based tools can cut DNA at selected sites, while base editors and prime editors are designed to make more precise changes without relying on the same type of double-strand break. In principle, editing could provide a durable correction after one treatment.

That durability is both an advantage and a risk. Unintended DNA changes may persist for the life of the cell and could be passed to daughter cells. Developers must examine editing at predicted and unpredicted genomic sites, as well as larger rearrangements that may not be detected by simple sequence checks. Delivery remains a central challenge, particularly when the affected cells are distributed throughout the body.

Ex vivo editing, in which cells are removed, modified, tested, and returned to the patient, offers more control over the treated cell population. It is most practical for blood and immune cells. In vivo editing is needed for many disorders of the brain, heart, liver, retina, or muscle, but it places greater demands on delivery precision and safety assessment.

Diagnosis becomes part of drug development

An individualized therapy is only as sound as the diagnosis on which it is based. Finding a rare variant is not enough. Researchers must determine whether it actually causes disease, how it changes RNA or protein function, and whether correcting that effect is likely to matter clinically.

This often requires functional studies using patient cells, engineered cell lines, organoids, or animal models. For suspected splicing variants, researchers may measure whether an exon is incorrectly included or omitted. For loss-of-function variants, they may evaluate protein abundance or cellular activity. These experiments can identify a treatment strategy, but they also consume time that may be scarce in rapidly progressive disease.

Timing is especially important in neurodevelopmental and neurodegenerative disorders. Restoring a missing protein may prevent further injury without repairing neurons or tissues that have already been lost. A therapy that appears biologically successful may produce little visible improvement if administered after irreversible damage. Earlier diagnosis through genome sequencing, newborn screening, and better interpretation of rare variants could therefore be as important as the therapeutic technology itself.

Not every pathogenic variant is treatable with current methods. Some diseases involve many genes, complex developmental processes, or widespread tissue damage. Others require tightly controlled gene expression that simple replacement cannot reproduce. Individualized therapy should be considered a possible route for selected molecular problems, not a universal answer to rare disease.

Evidence from very small populations

Traditional randomized trials may be impossible when only one or two eligible patients exist. This does not eliminate the need for evidence, but it changes how evidence must be assembled.

A well characterized natural history can show how untreated disease usually progresses. Repeated measurements before treatment may establish each patient's trajectory. Biomarkers can indicate whether the therapy reaches its target or changes the intended biological pathway. Objective clinical measures, such as seizure frequency, respiratory function, motor performance, vision, or a validated laboratory marker, can then be tracked after treatment.

Each source has weaknesses. Historical controls may differ in age, supportive care, genotype, or disease severity. A patient's condition may fluctuate naturally. Caregivers and clinicians know when treatment begins, which can influence subjective assessments. Biomarker improvement does not always translate into better survival or function.

For these reasons, evidence from an individualized therapy is often a chain of linked findings rather than one decisive comparison. The chain may include genetic causation, correction in laboratory models, validated product potency, target engagement in the patient, and a clinical course that differs meaningfully from expected progression. The credibility of the conclusion depends on the strength of every link.

Long-term follow-up is particularly important for durable gene therapies. Some risks, including delayed immune effects, loss of expression, or consequences of unintended genomic changes, may not become apparent during the initial treatment period.

Safety cannot be entirely individualized

A treatment made for one patient creates a difficult safety problem. Large preclinical studies can require more material, money, and time than production of the clinical dose itself. Yet reducing testing too far could expose a patient to poorly understood risks.

A platform approach offers a possible compromise. If several products use the same vector, oligonucleotide chemistry, manufacturing site, route of administration, and quality controls, some knowledge may be applicable across the group. Sequence-specific testing would still be needed where changing the sequence could alter binding, potency, distribution, or toxicity.

The United States Food and Drug Administration has issued guidance on investigational submissions for individualized antisense oligonucleotides. The guidance addresses chemistry, manufacturing, nonclinical information, clinical monitoring, and communication with the agency. Its existence reflects regulatory willingness to consider individualized products, but it does not create an automatic or accelerated path to treatment.

Independent review remains essential. Families confronting severe disease may reasonably accept substantial uncertainty, but urgency can make it difficult to distinguish a scientifically plausible intervention from one that is merely available. Ethics committees, regulators, clinicians, laboratory scientists, and patient representatives each contribute different forms of scrutiny.

Manufacturing is a central constraint

A genetic medicine must be more than correctly designed. It must be manufactured reproducibly, tested for identity and purity, stored appropriately, and released under quality standards suitable for human use.

For viral vectors, production may involve cell culture, purification, potency assays, tests for contamination, and measurement of functional vector content. For oligonucleotides, developers must confirm sequence identity, chemical composition, purity, sterility, and biological activity. Each assay must be sufficiently reliable to support a treatment decision.

Small batches are disproportionately expensive because many costs do not shrink with the number of doses. Facility preparation, method development, regulatory documentation, and quality review may be required whether a batch serves one patient or thousands. Limited capacity at specialized manufacturing sites can add delays.

Shared protocols and standardized analytical methods could reduce duplication. Centralized facilities might produce families of related products using established procedures. Digital records could make it easier to trace sequence design, raw materials, testing, and clinical outcomes. These changes would not make individualized medicines inexpensive, but they could make their development more predictable.

Access and ownership raise difficult questions

A system built around individual treatments could widen existing disparities. Patients at major academic centers may have access to genome sequencing, specialist interpretation, research laboratories, philanthropy, and regulatory expertise. Others with equally serious conditions may never receive a molecular diagnosis.

Funding is another unresolved issue. Commercial companies may hesitate to develop products with no conventional market. Academic teams and nonprofit organizations can fill some gaps, but donations and research grants are not dependable mechanisms for broad access. Insurers and public health systems must decide how to evaluate therapies supported by unconventional evidence and intended for extremely small populations.

Control of data and technology also matters. A patient's treatment may depend on patented editing tools, proprietary delivery systems, licensed manufacturing methods, or access to biological samples. Clear agreements are needed to determine who owns the product, who may use the resulting knowledge, and whether a successful design can be adapted for another patient.

Fair selection is especially challenging when capacity is limited. Disease severity, treatment feasibility, age, progression rate, quality of evidence, and likelihood of benefit may all be relevant. A transparent process is preferable to decisions driven largely by fundraising ability or public visibility.

A future built on reusable platforms

The most plausible future is not a separate development system for every patient. It is a collection of validated platforms that can be adapted within defined boundaries.

An oligonucleotide platform might use a familiar chemical backbone, delivery route, dose range, and safety monitoring plan while changing the targeting sequence. A gene therapy platform might hold the vector and production method constant while substituting a therapeutic cassette. An editing platform could reuse the delivery vehicle and editing enzyme while changing the guide RNA.

The scientific question is how much can safely remain constant before a sequence change effectively creates a new product. The answer will differ by technology. A small change in an ASO may alter unintended RNA binding. A new gene cassette may change protein expression or immune risk. A different editing guide may create a distinct pattern of genomic effects. Platform knowledge can narrow uncertainty, but it cannot erase it.

Patient registries and carefully structured data sharing could make each treatment more informative. Negative findings are as important as successes because they reveal which designs, biomarkers, or delivery methods do not work. Common outcome measures would make experiences across institutions easier to compare.

Individualized gene and RNA therapies are unlikely to replace conventional drug development. Their greater promise is to create a viable path for molecularly defined diseases that conventional markets and trial designs cannot accommodate. Progress will depend not only on more precise genetic tools, but also on faster diagnosis, credible evidence standards, adaptable regulation, reliable manufacturing, long-term surveillance, and fair access. If those systems mature together, the number of patients required to justify developing a medicine may no longer determine whether treatment is scientifically possible.